THE US Food and Drug
Administration has approved
Kcentra (prothrombin complex
concentrate, Human) for the urgent
reversal of vitamin K antagonist
(VKA) anticoagulation in adults with
acute major bleeding.
The only other product approved
for this use in the USA is plasma,
and like plasma Kcentra is used in
conjunction with the administration
of vitamin K to reverse the
anticoagulation effect.
Unlike plasma, Kcentra does
not require blood group typing or
thawing so can be administered
more quickly.
Kcentra is made from the
pooled plasma of healthy donors,
processed in a way to minimise the
risk of transmitting diseases.
It’s made by CSL Behring.The above article was sent to subscribers in Pharmacy Daily's issue from 01 May 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 May 13
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.